A federal outside panel voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is advisory only. The FDA has given no public comment on whether it will follow the advice. The move came after weeks of community hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could shift how the agency handles a part of the wellness market that is scaling quickly. Industry players are waiting to see if the agency takes up the plan. A representative for the regulator offered no deadline for a next move. Backers argue the change would broaden access to products users find useful. Critics warn that looser rules could allow poor oversight across a quickly growing market. The vote only plants the seed for a shift, and the ultimate call rests with the federal agency.